Abstract
Purpose: This was the first Phase I study to assess the safety and tolerability of the tablet formulation of olaparib (Lynparza™), an oral poly(ADP-ribose) polymerase inhibitor, in Japanese patients with advanced solid tumours. The pharmacokinetic profile and antitumour activity of olaparib tablets were also assessed. Methods: In this open-label, multicentre study (D081BC00001; NCT01813474), a single dose of olaparib (200 or 300 mg, tablets) was administered on day 1, followed 48 h afterwards by multiple dosing (200 or 300 mg twice daily [bid]) for 28-day cycles. Doses were escalated in successive cohorts, with an expansion cohort enrolled at the highest dose that was confirmed to be tolerable during dose escalation. Results: Twenty-eight patients were enrolled and 23 were treated (n = 4, 7 and 12 at 200, 300 and 300 [expansion] mg bid, respectively). No patients experienced a dose-limiting toxicity, so the maximum tolerated dose was not defined. The most frequent adverse events were nausea (43.5 %), decreased appetite (30.4 %), anaemia (26.1 %) and constipation (26.1 %). No patient had dose reductions, two had dose interruptions, and two discontinued treatment because of adverse events. Absorption of olaparib was rapid following single and multiple dosing, and plasma concentrations declined biphasically after single dosing. No patients had a confirmed antitumour response. Conclusions: Olaparib tablet doses of 200 and 300 mg bid were considered tolerable in Japanese patients with advanced solid tumours. Consistent with the global olaparib programme, 300 mg bid was selected as the recommended tablet dose for future studies. Clinical trial registration number: NCT01813474.
| Original language | English |
|---|---|
| Pages (from-to) | 525-531 |
| Number of pages | 7 |
| Journal | Cancer chemotherapy and pharmacology |
| Volume | 78 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Sep 1 2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Toxicology
- Pharmacology
- Cancer Research
- Pharmacology (medical)
Cite this
Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. / Yonemori, Kan; Tamura, Kenji; Kodaira, Makoto; Fujikawa, Koshi; Sagawa, Tamotsu; Esaki, Taito; Shirakawa, Tsuyoshi; Hirai, Fumihiko; Yokoi, Yuki; Kawata, Toshio; Hatano, Ben; Takahashi, Yasuo.
In: Cancer chemotherapy and pharmacology, Vol. 78, No. 3, 01.09.2016, p. 525-531.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
AU - Yonemori, Kan
AU - Tamura, Kenji
AU - Kodaira, Makoto
AU - Fujikawa, Koshi
AU - Sagawa, Tamotsu
AU - Esaki, Taito
AU - Shirakawa, Tsuyoshi
AU - Hirai, Fumihiko
AU - Yokoi, Yuki
AU - Kawata, Toshio
AU - Hatano, Ben
AU - Takahashi, Yasuo
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Purpose: This was the first Phase I study to assess the safety and tolerability of the tablet formulation of olaparib (Lynparza™), an oral poly(ADP-ribose) polymerase inhibitor, in Japanese patients with advanced solid tumours. The pharmacokinetic profile and antitumour activity of olaparib tablets were also assessed. Methods: In this open-label, multicentre study (D081BC00001; NCT01813474), a single dose of olaparib (200 or 300 mg, tablets) was administered on day 1, followed 48 h afterwards by multiple dosing (200 or 300 mg twice daily [bid]) for 28-day cycles. Doses were escalated in successive cohorts, with an expansion cohort enrolled at the highest dose that was confirmed to be tolerable during dose escalation. Results: Twenty-eight patients were enrolled and 23 were treated (n = 4, 7 and 12 at 200, 300 and 300 [expansion] mg bid, respectively). No patients experienced a dose-limiting toxicity, so the maximum tolerated dose was not defined. The most frequent adverse events were nausea (43.5 %), decreased appetite (30.4 %), anaemia (26.1 %) and constipation (26.1 %). No patient had dose reductions, two had dose interruptions, and two discontinued treatment because of adverse events. Absorption of olaparib was rapid following single and multiple dosing, and plasma concentrations declined biphasically after single dosing. No patients had a confirmed antitumour response. Conclusions: Olaparib tablet doses of 200 and 300 mg bid were considered tolerable in Japanese patients with advanced solid tumours. Consistent with the global olaparib programme, 300 mg bid was selected as the recommended tablet dose for future studies. Clinical trial registration number: NCT01813474.
AB - Purpose: This was the first Phase I study to assess the safety and tolerability of the tablet formulation of olaparib (Lynparza™), an oral poly(ADP-ribose) polymerase inhibitor, in Japanese patients with advanced solid tumours. The pharmacokinetic profile and antitumour activity of olaparib tablets were also assessed. Methods: In this open-label, multicentre study (D081BC00001; NCT01813474), a single dose of olaparib (200 or 300 mg, tablets) was administered on day 1, followed 48 h afterwards by multiple dosing (200 or 300 mg twice daily [bid]) for 28-day cycles. Doses were escalated in successive cohorts, with an expansion cohort enrolled at the highest dose that was confirmed to be tolerable during dose escalation. Results: Twenty-eight patients were enrolled and 23 were treated (n = 4, 7 and 12 at 200, 300 and 300 [expansion] mg bid, respectively). No patients experienced a dose-limiting toxicity, so the maximum tolerated dose was not defined. The most frequent adverse events were nausea (43.5 %), decreased appetite (30.4 %), anaemia (26.1 %) and constipation (26.1 %). No patient had dose reductions, two had dose interruptions, and two discontinued treatment because of adverse events. Absorption of olaparib was rapid following single and multiple dosing, and plasma concentrations declined biphasically after single dosing. No patients had a confirmed antitumour response. Conclusions: Olaparib tablet doses of 200 and 300 mg bid were considered tolerable in Japanese patients with advanced solid tumours. Consistent with the global olaparib programme, 300 mg bid was selected as the recommended tablet dose for future studies. Clinical trial registration number: NCT01813474.
UR - http://www.scopus.com/inward/record.url?scp=84978835906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978835906&partnerID=8YFLogxK
U2 - 10.1007/s00280-016-3106-7
DO - 10.1007/s00280-016-3106-7
M3 - Article
C2 - 27422301
AN - SCOPUS:84978835906
VL - 78
SP - 525
EP - 531
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 3
ER -